Jerome Stevens Pharmaceuticals,has ample supply to combat the announced shortage of Levoxyl©.

FOR IMMEDIATE RELEASE: UNITHROID© READILY AVAILABLE Jerome Stevens Pharmaceuticals, Inc. prepared to supply market due to Levoxyl© shortage April 4, 2013 BOHEMIA, NY – Jerome Stevens Pharmaceuticals, Inc., manufacturer of Unithroid©, the first FDA-approved Levothyroxine Sodium, USP therapy, announced today that it has ample supply to combat the announced shortage of Levoxyl©. Levoxyl©, distributed by Pfizer, ceased shipping all strengths of the product on February 13, 2013 and will not resume production until 2014. Jerome Stevens Pharmaceuticals, Inc. currently has ample inventory to combat the announced shortage and has begun increasing production for long-term supply relief. Pharmacists, patients, and healthcare providers can request additional information via email at inquiries@jeromestevens.com. Jerome Stevens Pharmaceuticals, Inc. is committed to bringing the highest-quality products to the consumer. As a family owned corporation, they understand the necessity for safety and quality and take the utmost pride in every product that leaves its doors. Jerome Stevens Pharmaceuticals, Inc. has not, and will not, sacrifice the quality that has become its staple, for a greater quantity of products as so many companies have today. You may visit the company website at JeromeStevens.com